(Reuters) - Food and Drug Administration staff said the 20-milligram dose of the drug, Zimulti, produced clinically significant weight loss over one year. An advisory panel will consider on Wednesday if regulators should approve U.S. sales.
Known generically as rimonabant, the drug already is sold in 18 countries under the name Acomplia.
Read more at Reuters.com Government Filings News
Known generically as rimonabant, the drug already is sold in 18 countries under the name Acomplia.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment